Kisplyx
What Kisplyx is used for
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Kisplyx
- Active substance
- lenvatinib
- Disease area
- Carcinoma, Renal Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE29
- Marketing authorisation holder
- Eisai GmbH
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kisplyx used for?
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
What is the active substance in Kisplyx?
Kisplyx contains lenvatinib.
Who makes Kisplyx?
The EU marketing authorisation holder is Eisai GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU